SABR boost and de-escalated chemoradiation for Human Papillomavirus
This trial is testing whether a shorter, more intense course of radiation therapy is as effective as the standard 7-week course for treating oropharynx cancer associated with the human papillomavirus.
- Human Papillomavirus
- Oropharyngeal Cancers
- Head and Neck Cancer
1 Primary · 8 Secondary · Reporting Duration: At 2- and 5-years after the end of chemoradiation
2 Treatment Groups
1 of 2
SABR boost and de-escalated chemoradiation
1 of 2
106 Total Participants · 2 Treatment Groups
Primary Treatment: SABR boost and de-escalated chemoradiation · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What risks are associated with SABR boost and de-escalated chemoradiation?
"SABR boost and de-escalated chemoradiation was given a safety score of 2. This is due to the lack of efficacy data, as this is only a Phase 2 trial." - Anonymous Online Contributor
How many people are being recruited for this research project?
"That is correct, according to the clinicaltrials.gov website, this study is currently looking for participants. The trial was first posted on February 23rd 2020 and was last edited on April 24th 2022. They are hoping to enroll 106 patients at a single site." - Anonymous Online Contributor
Are volunteers being accepted for this experiment currently?
"The most recent update on clinicaltrials.gov suggests that this trial is still looking for participants. The posting date was February 23rd, 2020 and the April 24th, 2022 update confirms that recruitment is ongoing." - Anonymous Online Contributor